LX9211

DRUG2 trials

Sponsors

Lexicon Pharmaceuticals

Conditions

DiabetesDiabetic Peripheral NeuropathyPostherpetic Neuralgia

Phase 2

Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain

CompletedNCT04455633

Lexicon PharmaceuticalsDiabetes, Diabetic Peripheral Neuropathy

Start: 2020-09-03End: 2022-06-28Updated: 2025-06-25

Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia

CompletedNCT04662281

Lexicon PharmaceuticalsPostherpetic Neuralgia

Start: 2020-12-10End: 2022-12-28Updated: 2026-02-13

Related Papers

Discovery of (<i>S</i>)-1-((2′,6-Bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine (BMS-986176/LX-9211): A Highly Selective, CNS Penetrable, and Orally Active Adaptor Protein-2 Associated Kinase 1 Inhibitor in Clinical Trials for the Treatment of Neuropathic Pain

Journal of Medicinal Chemistry2022-03-0826 citations